TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38095939

Group type: EXPERIMENTAL
Intervention: Higher morning positive affect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher morning negative affect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher characteristic morning positive affect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher characteristic morning negative affect
Number of subjects: 0
Study: 38096002

Group type: EXPERIMENTAL
Intervention: Decision support system (DSS) and machine learning web application for 3 months (experimental group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not exposed to the DSS and machine learning web application (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Weekly medication diary and standardized self-reports (both groups)
Number of subjects: 100
Study: 38096017

Group type: EXPERIMENTAL
Intervention: MedAdhere app
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 38096020

Group type: EXPERIMENTAL
Intervention: Afini intervention group (1175 caregiver-child dyads)
Number of subjects: 2471

Group type: EXPERIMENTAL
Intervention: Home visit intervention group (316 caregiver-child dyads)
Number of subjects: 2471

Group type: COMPARATOR
Intervention: Control group (980 caregiver-child dyads)
Number of subjects: 2471

Group type: EXPERIMENTAL
Intervention: Afini intervention group
Number of subjects: 2471

Group type: EXPERIMENTAL
Intervention: Home visit intervention group
Number of subjects: 2471

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2471
Study: 38096102

Group type: EXPERIMENTAL
Intervention: MKI therapy (cohort 1)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Active surveillance (cohort 2)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Active surveillance transitioning to MKI therapy (cohort 2)
Number of subjects: 647
Study: 38096105

Group type: EXPERIMENTAL
Intervention: Adjunctive systemic corticosteroids
Number of subjects: 0
Study: 38096106

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GLP1-mediated weight loss
Number of subjects: 0
Study: 38096190

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 0
Study: 38096261

Group type: EXPERIMENTAL
Intervention: Cranberry juice or cranberry products
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38096402

Group type: EXPERIMENTAL
Intervention: Ontamalimab 25 mg induction therapy
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Ontamalimab 75 mg induction therapy
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Ontamalimab 25 mg maintenance therapy
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Ontamalimab 75 mg maintenance therapy
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 1025
Study: 38096461

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) plus chemotherapy (bendamustine, CHOP, or CVP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab (R) plus chemotherapy (bendamustine, CHOP, or CVP)
Number of subjects: 0
Study: 38096462

Group type: EXPERIMENTAL
Intervention: PEG-L-Asparaginase (PEG-ASNASE, 2,500 IU/sqm once a week × 4)
Number of subjects: 1097
Study: 38096472

Group type: EXPERIMENTAL
Intervention: Cobimetinib plus vemurafenib
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 31
Study: 38096705

Group type: EXPERIMENTAL
Intervention: Oral azithromycin ± amoxicillin
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: None/primary education (vs university)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Cesarean birth
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Antibiotic receipt per physician discretion (vs for cesarean prophylaxis)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: 3 factor model (cesarean birth, receipt of antibiotics per physician discretion, university education)
Number of subjects: 652
Study: 38096764

Group type: EXPERIMENTAL
Intervention: Neovaginal reconstruction
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Flap reconstruction
Number of subjects: 334

Group type: COMPARATOR
Intervention: No reconstruction
Number of subjects: 334
Study: 38096946

Group type: EXPERIMENTAL
Intervention: Providing patient-specific out-of-pocket cost estimates during clinical encounters.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group without access to patient-specific out-of-pocket cost estimates.
Number of subjects: 0
Study: 38097379

Group type: EXPERIMENTAL
Intervention: Multiplex molecular testing
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Pre-intervention testing
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: Intervention testing
Number of subjects: 1157
Study: 38097552

Group type: EXPERIMENTAL
Intervention: VRC01 (broadly neutralizing monoclonal antibody)
Number of subjects: 0
Study: 38097605

Group type: EXPERIMENTAL
Intervention: Pyrotinib plus docetaxel
Number of subjects: 0
Study: 38097741

Group type: EXPERIMENTAL
Intervention: Olaparib (O) maintenance therapy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Olaparib (O)
Number of subjects: 182
Study: 38097862

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 4304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study: 38097898

Group type: EXPERIMENTAL
Intervention: Lactation management model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine lactation practices in clinic (Control)
Number of subjects: 0
Study: 38097899

Group type: EXPERIMENTAL
Intervention: Perineal Massage and Warm Compresses (PeMWaC)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Control group (hands-on)
Number of subjects: 496
Study: 38097933

Group type: EXPERIMENTAL
Intervention: Wearable device intervention with behavioral change techniques (BCTs) for physical activity promotion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 40
Study: 38097963

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) with 6% low-protein formula (6% LPF) and dietary counseling
Number of subjects: 66

Group type: COMPARATOR
Intervention: Low-protein diet (LPD) counseling alone
Number of subjects: 66
Study: 38098022

Group type: EXPERIMENTAL
Intervention: S. persica chewing stick (MCS)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: S. persica toothbrush (MTB)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard toothbrush (STB)
Number of subjects: 78

Group type: COMPARATOR
Intervention: All groups (MCS, MTB, STB)
Number of subjects: 78
Study: 38098024

Group type: EXPERIMENTAL
Intervention: Coated TKA
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard TKA
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Coated TKA in allergy patients
Number of subjects: 76

Group type: COMPARATOR
Intervention: Matched-pair group receiving coated implant
Number of subjects: 76
Study: 38098072

Group type: EXPERIMENTAL
Intervention: Edoxaban interruption in major surgeries
Number of subjects: 788

Group type: COMPARATOR
Intervention: Edoxaban interruption in nonmajor surgeries
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Preprocedural-only interruption in major surgeries
Number of subjects: 788

Group type: COMPARATOR
Intervention: Preprocedural-only interruption in nonmajor surgeries
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Postprocedural-only interruption in major surgeries
Number of subjects: 788

Group type: COMPARATOR
Intervention: Postprocedural-only interruption in nonmajor surgeries
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Bleeding rates in major surgeries
Number of subjects: 788

Group type: COMPARATOR
Intervention: Bleeding rates in nonmajor surgeries
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Overall event rates for bleeding and thromboembolic events
Number of subjects: 788
Study: 38098080

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 1553

Group type: COMPARATOR
Intervention: Non-obstructive sleep apnea (non-OSA)
Number of subjects: 1553
Study: 38098079

Group type: EXPERIMENTAL
Intervention: Engaged leadership strategies
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Leadership involvement and mentorship during the intervention
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Training prioritizing leadership visibility and open communication
Number of subjects: 39
Study: 38098145

Group type: EXPERIMENTAL
Intervention: ASCS + more widely meshed STSG
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard-of-care meshed STSG (control)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: ASCS + more widely meshed STSG and Standard-of-care meshed STSG (control)
Number of subjects: 65
Study: 38098221

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg/day for 3 days and 200 mg/day for 11 days
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 116
Study: 38098261

Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 68
Study: 38098635

Group type: EXPERIMENTAL
Intervention: Ensemble program
Number of subjects: 149

Group type: COMPARATOR
Intervention: SAU (support as usual)
Number of subjects: 149
Study: 38098734

Group type: EXPERIMENTAL
Intervention: Digital Therapy for Obesity App (DTxO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 38098848

Group type: EXPERIMENTAL
Intervention: Direct epiglottis lifting
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Hyperangulated videolaryngoscopy
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Direct epiglottis lifting with hyperangulated videolaryngoscope
Number of subjects: 129

Group type: COMPARATOR
Intervention: Macintosh videolaryngoscopy
Number of subjects: 129
Study: 38099081

Group type: EXPERIMENTAL
Intervention: Accelerated high-dose theta burst stimulation (ahTBS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 1-Hz repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 45
Study: 38099334

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38099506

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 1187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1187
Study: 38099673

Group type: EXPERIMENTAL
Intervention: GST-HG171 (150-900 mg single ascending doses)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: GST-HG171 (150 and 300 mg multiple ascending doses)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: GST-HG171/ritonavir (150/100 mg BID for 5 days)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: GST-HG171/ritonavir (150/100 mg BID)
Number of subjects: 78
Study: 38099732

Group type: EXPERIMENTAL
Intervention: PROSPECT model predicting post-ICU health problems at 3 months
Number of subjects: 2476
Study: 38099912

Group type: EXPERIMENTAL
Intervention: PASCAL
Number of subjects: 180

Group type: COMPARATOR
Intervention: MitraClip
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Smaller flail gap
Number of subjects: 180
Study: 38099944

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 2565

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2565
Study: 38100078

Group type: EXPERIMENTAL
Intervention: Diquafosol Sodium Ophthalmic Solution, dosage and duration not available
Number of subjects: 0
Study: 38100098

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38100110

Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose, biannual administration over 2 years)
Number of subjects: 76092

Group type: COMPARATOR
Intervention: Placebo (matching placebo, biannual administration over 2 years)
Number of subjects: 76092
Study: 38100172

Group type: EXPERIMENTAL
Intervention: Health education program including face-to-face counseling on lifestyle modifications, blood pressure monitoring, and medication compliance-related health education during enrollment and monthly follow-ups.
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 432

Group type: COMPARATOR
Intervention: Usual care from the hospital
Number of subjects: 432
Study: 38100226

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 70
Study: 38100451

Group type: EXPERIMENTAL
Intervention: Familias con Orgullo
Number of subjects: 306

Group type: COMPARATOR
Intervention: Prevention as usual
Number of subjects: 306
Study: 38100477

Group type: EXPERIMENTAL
Intervention: Caring Mindfulness-Based Approach for Seniors (CMBAS)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Health Self-Management Programme (HSMP)
Number of subjects: 147
Study: 38100536

Group type: EXPERIMENTAL
Intervention: Recombinant vaccinia virus expressing Nipah virus glycoprotein (G)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant vaccinia virus expressing Nipah virus fusion (F) protein
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other vaccinia virus vectors (control group)
Number of subjects: 0
Study: 38100679

Group type: EXPERIMENTAL
Intervention: Mepolizumab 300 mg subcutaneously every four weeks
Number of subjects: 118
Study: 38100820

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Waist Circumference
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Handgrip
Number of subjects: 150
Study: 38101205

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PB)
Number of subjects: 20
Study: 38101250

Group type: EXPERIMENTAL
Intervention: HEPPI (Homebound Elderly People Psychotherapeutic Intervention)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 199
Study: 38101301

Group type: EXPERIMENTAL
Intervention: AADvac1 (active immunotherapy against pathological tau protein)
Number of subjects: 119
Study: 38101315

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Before surgery
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: One year after laparoscopic sleeve gastrectomy
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 116
Study: 38101431

Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy (1200 mg IV every 3 weeks)
Number of subjects: 1213

Group type: COMPARATOR
Intervention: Placebo plus platinum-based chemotherapy
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy
Number of subjects: 1213
Study: 38101433

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus platinum-based chemotherapy (group A)
Number of subjects: 1213

Group type: COMPARATOR
Intervention: Placebo plus platinum-based chemotherapy (group C)
Number of subjects: 1213
Study: 38101437

Group type: EXPERIMENTAL
Intervention: Sunvozertinib 300 mg once daily until meeting discontinuation criteria
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Sunvozertinib 300 mg once daily
Number of subjects: 104
Study: 38101429

Group type: EXPERIMENTAL
Intervention: Genetically confirmed diagnosis of familial hypercholesterolaemia
Number of subjects: 11848

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of familial hypercholesterolaemia
Number of subjects: 11848

Group type: EXPERIMENTAL
Intervention: Lipid-lowering medication (LLM) usage
Number of subjects: 11848

Group type: COMPARATOR
Intervention: Genetic diagnosis vs. clinical criteria
Number of subjects: 11848

Group type: EXPERIMENTAL
Intervention: Familial-hypercholesterolaemia-related physical signs and cardiovascular risk factors
Number of subjects: 11848
Study: 38101517

Group type: EXPERIMENTAL
Intervention: Weight Loss Intervention
Number of subjects: 81
Study: 38101756

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) plus prednisolone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Azathioprine plus prednisolone
Number of subjects: 70
Study: 38101824

Group type: EXPERIMENTAL
Intervention: 4-day intensive cognitive behavioural therapy (B4DT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Individual cognitive behavioural therapy (standard CBT)
Number of subjects: 120
Study: 38101830

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with deproteinisation using Papacárie Duo
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with deproteinisation using 5% sodium hypochlorite solution
Number of subjects: 3

Group type: COMPARATOR
Intervention: Selective removal of carious dentinal tissue using a curette (Control group)
Number of subjects: 3
Study: 38101840

Group type: EXPERIMENTAL
Intervention: Potassium binders (PB) treatment for hyperkalaemia (HK)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Control of serum potassium (S-K)
Number of subjects: 350
Study: 38101846

Group type: EXPERIMENTAL
Intervention: Bowel ultrasound (BUS) for monitoring inflammation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bowel ultrasound (BUS)
Number of subjects: 50
Study: 38101850

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) programme
Number of subjects: 81

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 81
Study: 38101851

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) administered at primary motor cortex
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) administered at primary sensory cortex
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) administered at dorsolateral prefrontal cortex
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sham control group
Number of subjects: 88
Study: 38101860

Group type: EXPERIMENTAL
Intervention: pTVG-HP (100 µg administered intradermally) and nivolumab (240 mg intravenous infusion) every 2 weeks for 3 months, then every 4 weeks for 1 year.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study: 38101861

Group type: EXPERIMENTAL
Intervention: Intravesical Ty21a
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard BCG
Number of subjects: 25
Study: 38101901

Group type: EXPERIMENTAL
Intervention: 2.5 mg NLY01
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: 5.0 mg NLY01
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 38101904

Group type: EXPERIMENTAL
Intervention: Cerliponase alfa (300 mg) administered via intracerebroventricular infusion every 2 weeks for a mean of 272.1 weeks.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Historical controls with untreated CLN2 disease from the DEM-CHILD database.
Number of subjects: 24
Study: 38101902

Group type: EXPERIMENTAL
Intervention: Milvexian 25 mg once daily
Number of subjects: 2366

Group type: EXPERIMENTAL
Intervention: Milvexian 25 mg twice daily
Number of subjects: 2366

Group type: EXPERIMENTAL
Intervention: Milvexian 50 mg twice daily
Number of subjects: 2366

Group type: EXPERIMENTAL
Intervention: Milvexian 100 mg twice daily
Number of subjects: 2366

Group type: EXPERIMENTAL
Intervention: Milvexian 200 mg twice daily
Number of subjects: 2366

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2366
Study: 38101918

Group type: EXPERIMENTAL
Intervention: BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: BASDAI individual items
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome scores
Number of subjects: 119
Study: 38101923

Group type: EXPERIMENTAL
Intervention: Chair placement (≤3 feet (0.9 m) of patient's bedside and facing the bed)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual chair location (control)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Chair placement
Number of subjects: 125
Study: 38101984

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 45
Study: 38102013

Group type: EXPERIMENTAL
Intervention: Transient genicular artery embolization (GAE) using an ethiodized oil-based emulsion (mixture of ioversol and ethiodized oil in a 1:3 ratio)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Transient genicular artery embolization (GAE) using an ethiodized oil-based emulsion
Number of subjects: 22
Study: 38102152

Group type: EXPERIMENTAL
Intervention: Ketogenic feeding
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard enteral feeding (Control)
Number of subjects: 29
Study: 38102226

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/d
Number of subjects: 42
Study: 38102448

Group type: EXPERIMENTAL
Intervention: 7-day antimicrobial therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 14-day antimicrobial therapy
Number of subjects: 0
Study: 38102496

Group type: EXPERIMENTAL
Intervention: BRIGHT (cognitive behavioral therapy)
Number of subjects: 44

Group type: COMPARATOR
Intervention: AC (attention control)
Number of subjects: 44
Study: 38102527

Group type: EXPERIMENTAL
Intervention: One change to childbirth plan
Number of subjects: 3532

Group type: EXPERIMENTAL
Intervention: Two changes to childbirth plan
Number of subjects: 3532

Group type: EXPERIMENTAL
Intervention: One change in childbirth plan (primigravida)
Number of subjects: 3532
Study: 38102530

Group type: EXPERIMENTAL
Intervention: Text message reminders (received if the PCD had not been used for 2 consecutive days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups (pooled population)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Full compliance (both groups)
Number of subjects: 29
Study: 38102535

Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg
Number of subjects: 193

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 193
Study: 38102536

Group type: EXPERIMENTAL
Intervention: Supervised endurance group (SEG, n=30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Supervised strength group (SSG, n=30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Supervised concurrent group (SCG, n=30)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (CG, n=30)
Number of subjects: 120